Could removing blood before surgery reduce transfusions in ovarian cancer patients?

NCT ID NCT06290193

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a technique called acute normovolemic hemodilution (ANH) in 86 women having surgery for advanced ovarian cancer. Before surgery, some blood is removed and stored, then returned during or after the operation. The goal is to see if this reduces the need for donor blood transfusions. Participants are randomly assigned to receive ANH or standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

acute normovolemic hemodilution (ANH) - a procedure where some blood is removed before surgery and returned later

What this could lead to

If it works, this technique could reduce the need for donor blood transfusions during ovarian cancer surgery, lowering risks like infection or allergic reactions.

What could go wrong

This is a small, early-phase trial (86 people) testing a procedure, not a new drug. It may not significantly reduce transfusions, and the technique itself carries risks like low blood pressure or anemia during surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer fallopian tube carcinoma fallopian tube neoplasm ovarian cancer ovarian carcinoma peritoneal carcinoma peritoneum cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities)

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Bergen (Limited protocol activities)

    RECRUITING

    Montvale, New Jersey, 07645, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center (All protocol activities)

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)

    RECRUITING

    Commack, New York, 11725, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Monmouth (Limited protocol activities)

    RECRUITING

    Middletown, New Jersey, 07748, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    RECRUITING

    Uniondale, New York, 11553, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Westchester (Limited protocol activities)

    RECRUITING

    Harrison, New York, 10604, United States

    Contact Phone: •••-•••-••••